Page last updated: 2024-11-05

dimyristoylphosphatidylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimyristoylphosphatidylcholine (DMPC) is a phospholipid composed of two myristate (14:0) fatty acyl chains linked to a glycerol backbone via ester bonds. It is a commonly used model membrane lipid in biophysical studies, particularly in the study of membrane structure and dynamics. DMPC is known for its ability to form liposomes, which are spherical vesicles that encapsulate an aqueous solution. These liposomes are used as model systems for studying the properties of cell membranes, including permeability, fluidity, and interactions with proteins and other molecules. DMPC is also used as a component of artificial membranes in various applications, such as drug delivery and biomimetic materials. The synthesis of DMPC typically involves the reaction of glycerol with two molecules of myristoyl chloride followed by the addition of phosphorylcholine. DMPC is studied to understand the fundamental properties of lipid bilayers, the building blocks of cell membranes. It is used to investigate the effects of various factors, such as temperature, pH, and the presence of other molecules, on membrane structure and function. Researchers use DMPC to develop new drug delivery systems, investigate the mechanisms of protein-membrane interactions, and study the behavior of lipid rafts, which are specialized microdomains within cell membranes.'

1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID26197
CHEMBL ID316257
CHEBI ID241349
SCHEMBL ID244839
MeSH IDM0006471
PubMed CID5459377
CHEMBL ID451503
CHEBI ID45240
SCHEMBL ID37475
MeSH IDM0006471

Synonyms (136)

Synonym
CHEMBL316257
l-alpha-dimyristoylphosphatidylcholine
1,2-dimyristoyl-rac-glycero-3-phosphocholine
NCGC00181029-01
1,2-dimyristoyl-rac-glycero-3-phosphocholine, >=99%
D-5665
D-5667
13699-48-4
dimyristoyllecithin
2,3-di(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
18656-38-7
2,3-bis(tetradecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
chebi:241349 ,
2,3-bis(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
dimyristoyl-phosphatidylcholine
[2-({[2,3-bis(tetradecanoyloxy)propyl] phosphonato}oxy)ethyl]trimethylazanium
(1)-(7-myristoyl-4-oxido-10-oxo-3,5,9-trioxa-4-phosphatricosyl)trimethylammonium 4-oxide
2,3-bis(1-oxotetradecoxy)propyl 2-(trimethylammonio)ethyl phosphate
A839808
3,5,9-trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxotetradecyl)oxy)-, inner salt, 4-oxide
dimyristoylphosphatidylcholine, dl-
dtxsid4046816 ,
dtxcid2026816
tox21_112679
cas-18656-38-7
1,2-ditetradecanoyl-rac-glycerol-3-phosphocholine
einecs 242-481-1
u86zgc74v5 ,
unii-u86zgc74v5
FT-0625421
FT-0627667
FT-0627775
SCHEMBL244839
1,2-dimyristoyl-glycero-3-phosphocholine, dl-
alf component dmpc
dimyristoyl-.alpha.-lecithin
1,2-dimyristoyl-glycero-3-phosphocholine, (+/-)-
1,2-dimyristoyl-dl-phosphatidylcholine
1,2-dimyristoyl-phosphatidylcholine, (+/-)-
1,2-dimyristoyl-phosphatidylcholine
army liposome formulation component dmpc
1,2-dimyristoyl-glycero-3-phosphocholine
alfq component dmpc
dimyristoyl phosphatidylcholine, (+/-)-
dl-dimyristoylphosphatidylcholine
AKOS024418777
dl-beta,gamma-dimyristoyl-alpha-lecithin
mfcd00066562
dl-,-dimyristoyl--lecithin
CS-0204636
DB11283
Q27225712
soy bean phospholipid
3,5,9-trioxa-4-phosphatricosan-1-aminium,4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-,inner salt,4-oxide
HY-W142596
EN300-7397752
(2-{[2,3-bis(tetradecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
1,2-dimyristoyl-d54-sn-glycero-3-phosphocholine-1,1,2,2-d4-n,n,n-trimethyl-d9
LMGP01010477
beta,gamma-dimyristoyl l-alpha-phosphatidylcholine
dimyristoyl phosphatidylcholine
choline, phosphate, ester with l-1,2-dimyristin
1,2-dimyristoylphosphatidylcholine
1,2-bis(myristoyl)-sn-glycerophosphocholine
1,2-dimyristoyl-l-3-phosphatidylcholine
1,2-dimyristoyl-sn-glycero-3-phosphocholine
pc(14:0/14:0)
1,2-ditetradecanoyl-sn-glycero-3-phosphocholine
1,2-dimyristoyl-sn-glycero-3-phosphocholine, synthetic, ~99%
1,2-dimyristoyl-sn-glycero-3-phosphocholine, >=99%
dimyristoyl lecithin
DIMYRISTOYLPHOSPHATIDYLCHOLINE ,
choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-dimyristin, l-
dmpc, l-
dmpc, r-
18194-24-6
[(2r)-2,3-di(tetradecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
CHEMBL451503
chebi:45240 ,
dmpc
D3924
(r)-2,3-bis(tetradecanoyloxy)propyl [2-(trimethylammonio)ethyl] phosphate
einecs 242-085-9
52qk2nz2t0 ,
unii-52qk2nz2t0
(r)-(7-myristoyl-4-oxido-10-oxo-3,5,9-trioxa-4-phosphatricosyl)trimethylammonium 4-oxide
1,2-di-o-tetradecanoyl-sn-glycero-3-phosphocholine
1,2-di-o-myristoyl-sn-glycero-3-phosphocholine
gpc(14:0/14:0)
phosphatidylcholine(28:0)
(2r)-2,3-bis(tetradecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
1,2-dimyristoyl-gpc
gpc(28:0)
pc(28:0)
phosphatidylcholine(14:0/14:0)
l-|a,|a-dimyristoyl-|a-lecithin
3,5,9-trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxotetradecyl)oxy)-, inner salt, 4-oxide, (7r)-
dimyristoylphosphatidylcholine, l-
1,2-dimyristoyl-sn-glycero-3-phosphocholine [ii]
1,2-dimyristoyl-phosphatidylcholine, r-
dimyristoyl phosphatidylcholine, r-isomer
dimyristoyl lecithin [orange book]
dimyristoylphosphatidylcholine, r-
dimyristoyl phosphatidylcholine, l-
EPITOPE ID:156814
gpcho(28:0)
pc 28:0
SCHEMBL37475
CITHEXJVPOWHKC-UUWRZZSWSA-N
14:0 pc
1,2-dimyristoyl-3-lecithin
mfcd00036901
3,5,9-trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (r)-
AKOS027328056
(2-{[(2r)-2,3-bis(tetradecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium
GS-6403
gpcho(14:0/14:0)
(r)-2,3-bis(tetradecanoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
dmpc;l-,-dimyristoyl--lecithin
14:0 pc (dmpc), 1,2-dimyristoyl-sn-glycero-3-phosphocholine, powder
1,2-dimyristoyl-sn-glycero-3-phosphorylcholine
Q27120592
l-a-phosphatidylcholinedimyristoyl
BCP11746
dimyristoyl
1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine
EX-A5411
BP-26309
H10469
HY-109541
A852493
dimyristoyl phosphatidylcholine;(r)-2,3-bis(tetradecanoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
DTXSID00860227
1,2-dimyristoyl-l-phosphatidylcholine
CS-0031281
(r)-2,3-bis(tetradecanoyloxy)propyl(2-(trimethylammonio)ethyl)phosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Diacyl-TAP was less toxic than SA, and DPPC was less toxic than DMPC."( Multivariate toxicity screening of liposomal formulations on a human buccal cell line.
Jacobsen, J; Sande, SA; Smistad, G, 2007
)
0.34
"We have developed a fluorescence method to examine how membrane sterol lateral organization affects the potency of antioxidants, and used this information to evaluate possible adverse effects of lipid-soluble antioxidants seen in recent clinical studies."( Sterol superlattice affects antioxidant potency and can be used to assess adverse effects of antioxidants.
Chong, PL; Olsher, M, 2008
)
0.35
"Curcumin is a multi-functional and pharmacologically safe natural agent."( An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells.
Burke, TG; Chen, C; Gedaly, R; Jeon, H; Johnston, TD; McHugh, PP; Ranjan, D, 2009
)
0.35
" In order to gain insight on its toxic effects, intact red blood cells (RBC), human erythrocyte membranes and molecular models were used."( Toxic effects of the anticancer drug epirubicin in vitro assayed in human erythrocytes.
Aguilar, LF; Colina, JR; Contreras, D; Jemiola-Rzeminska, M; Petit, K; Strzalka, K; Suwalsky, M, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"25h) in the body resulting in enhanced half-life of d4T (23."( Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes.
Dutta, T; Garg, M; Jain, NK, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, methods developed in these experiments will facilitate future studies of the bioavailability of endogenous BaP on carbon blacks, especially in terms of determining the experimental conditions under which elution may occur."( Elution of benzo[a]pyrene from carbon blacks into biomembranes in vitro.
Bevan, DR; Worrell, WJ, 1985
)
0.27
" This technique provides a convenient method for evaluating the potential bioavailability of PAH associated with other carbonaceous particulates which occur in the environment."( In vitro technique to study elution of benzo[a]pyrene from particulates into biomembranes with application to woodstove particulates.
Bevan, DR; Yonda, NT, 1985
)
0.27
" Data were analysed by non-compartmental analysis, in order to evaluate the elimination constant, the half-life, the area under the curve and the bioavailability for each system."( The use of additives to modulate the release of a sparingly water soluble drug entrapped in PLA50 microparticles: in vivo investigation.
Coudane, J; Mallard, C; Rault, I; Vert, M,
)
0.13
" To improve the bioavailability of the synthesized prodrugs, they were encapsulated in unilamellar liposomes of dimiristoylphosphatidylcholine (DMPC) and cholesterol (CHOL)."( Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Braghiroli, D; Cannazza, G; Carafa, M; Di Stefano, A; Marianecci, C; Orlando, G; Pinnen, F; Ricciutelli, M; Santucci, E; Sozio, P, 2004
)
0.32
" Its stability as well as bioavailability can be increased by making prodrugs."( Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry.
Castelli, F; Cattel, L; Ceruti, M; Rocco, F; Sarpietro, MG,
)
0.13
"The stability and bioavailability of anticancer agents, such as gemcitabine, can be increased by forming prodrugs."( Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique.
Castelli, F; Cattel, L; Ceruti, M; Rocco, F; Sarpietro, MG, 2007
)
0.34
" In spite of its safety and efficacy, the in vivo bioavailability of curcumin is poor, and this may be a major obstacle to its utility as a therapeutic agent."( An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells.
Burke, TG; Chen, C; Gedaly, R; Jeon, H; Johnston, TD; McHugh, PP; Ranjan, D, 2009
)
0.35
" To improve the bioavailability of the dopamine prodrug, 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DOPH), it was encapsulated in unilamellar liposomes of dimiristoylphosphatidylcholine (DMPC) and cholesterol."( Potential dopamine prodrug-loaded liposomes: preparation, characterization, and in vitro stability studies.
Carafa, M; De Caro, V; Di Marzio, L; Giandalia, G; Giannola, LI; Marianecci, C; Santucci, E, 2010
)
0.36
" However, absorption and metabolism of flavonoids are complex processes that determine its bioavailability which remain not clear until now."( Hesperidin and hesperetin membrane interaction: understanding the role of 7-O-glycoside moiety in flavonoids.
Creczynski-Pasa, T; Jaramillo, C; Lima, VR; Londoño-Londoño, J, 2010
)
0.36
" A small amount of carrier phospholipid significantly increases the rate and the extent of dissolution, which may increase the bioavailability of ibuprofen."( Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.
Brausch, JF; Hussain, MD; Saxena, V; Talukder, RM, 2012
)
0.38
" In conclusion, intranasal administration of chitosan coated liposome appeared to be effective to enhance the bioavailability as well as prolonged exposure of fexofenadine in rats."( Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Han, HK; Lee, BJ; Qiang, F; Shin, HJ, 2012
)
0.38
" However, CBD-CS are preferred due to a better stability in water and improved bioavailability of siRNA on their surface."( siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles.
Bryszewska, M; de la Mata, FJ; Garaiova, Z; Gomez-Ramirez, R; Hianik, T; Ionov, M; Klajnert, B; Pędziwiatr-Werbicka, E; Waczulikova, I; Wróbel, D, 2012
)
0.38
" Our results suggest that these SLN could be regarded as a promising drug delivery system to improve IDE bioavailability and antioxidant activity."( Idebenone loaded solid lipid nanoparticles interact with biomembrane models: calorimetric evidence.
Castelli, F; Montenegro, L; Ottimo, S; Puglisi, G; Sarpietro, MG, 2012
)
0.38
" Membrane mimetic models were used to evaluate the RFB2's membrane partition, its preferential location across the membrane, and the effect of RFB2 on the biophysical properties of the membrane, which ultimately might be related with the antimycobacterial compound bioavailability and the membrane toxicity."( Drug-membrane interaction studies applied to N'-acetyl-rifabutin.
Arêde, M; Caio, JM; Lúcio, M; Moiteiro, C; Pinheiro, M; Reis, S, 2013
)
0.39
"Developed nanocochleates markedly improved anticancer efficacy, bioavailability and safety of fisetin."( Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study.
Bothiraja, C; Pawar, AP; Shaikh, KS; Thorat, UH; Yojana, BD, 2014
)
0.4
"A new family of biofunctionalized chitosan decorated nanocochleates-mediated drug delivery system was developed that involves uniquely combining nanocochleates with anticancer drug for controlled drug release, targeted delivery, improved bioavailability with reduced toxicity."( Development of novel biofunctionalized chitosan decorated nanocochleates as a cancer targeted drug delivery platform.
Bothiraja, C; Panda, B; Pawar, A; Poudel, I; Rajalakshmi, S; Rajput, N, 2018
)
0.48
" Fluorine substitution may increase a molecule's lipophilicity, thereby enabling its diffusion across cell membranes to enhance bioavailability or to exert a direct physiological effect from within the lipid bilayer."( Average orientation of a fluoroaromatic molecule in lipid bilayers from DFT-informed NMR measurements of
Coogan, MP; Griffin, JM; Hughes, E; Middleton, DA, 2018
)
0.48
" However, its pharmacological activity is reduced due MTIC low bioavailability in the brain."( Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ, 2019
)
0.51
"Gemcitabine (Gem) is a key drug for pancreatic cancer, yet limited by high systemic toxicity, low bioavailability and poor pharmacokinetic profiles."( Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
Bean, PA; Bulanadi, JC; de Campo, L; Gong, X; Julovi, SM; Moghaddam, MJ; Smith, RC; Xue, A, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" The danger of inferring an effect at clinical concentrations from data obtained at much higher levels is illustrated by a statistical analysis of our dose-response curves."( Do clinical levels of general anaesthetics affect lipid bilayers? Evidence from Raman scattering.
Kovalycsik, M; Lieb, WR; Mendelsohn, R, 1982
)
0.26
" Six of the 10 cats were given doses of L-NDDP at the maximum tolerated dosage (100 mg/m2) or a lower dosage (75 mg of L-NDDP/m2) at 21-day intervals, for a total of 4 treatments."( Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats.
Calderwood-Mays, M; Fox, LE; Khokhar, AR; Kubilis, P; MacEwen, EG; Perez-Soler, R; Toshach, K, 1999
)
0.3
"The objective of this work is to study the interaction of a copolymer, poly methyl vinyl ether/maleic anhydride (PMV/MA) used in pharmaceutical dosage form and a phospholipid L-alpha-dimiristoyl phosphatidylcholine (DMPC) with the aim of developing a bioadhesive system."( Interaction of poly methyl vinyl ether/maleic anhydride-dimiristoyl phosphatidylcholine: a model bioadhesion study.
Ballesteros, MP; Castro, RM; Lastres, JL; Nuñez, JL, 2000
)
0.31
"A novel dialysis adapter has been developed for USP apparatus 4 for in vitro release testing of dispersed system dosage forms."( A novel USP apparatus 4 based release testing method for dispersed systems.
Bhardwaj, U; Burgess, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antigenAny substance that stimulates an immune response in the body, such as through antibody production or by presentation to a T-cell receptor after binding to a major histocompability complex (MHC).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phosphatidylcholineA glycerophosphocholine that is glycero-3-phosphocholine bearing two acyl substituents at positions 1 and 2.
1,2-diacyl-sn-glycero-3-phosphocholineThe conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group.
phosphatidylcholine 28:0A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 28 carbons in total with 0 double bonds.
tetradecanoate esterA fatty acid ester obtained by condensation of the carboxy group of tetradecanoic acid (also known as myristic acid) with a hydroxy group of an alcohol or phenol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Lysolipid Incorporation into Mitochondria514
Lysolipid Incorporation into ER1023
Lysolipid Incorporation into ER PC(14:0/14:0)1023
Lysolipid incorporation into Mitochondria PC(14:0/14:0)514
Phosphatidylcholine Biosynthesis PC(14:0/14:0)620
Phosphatidylethanolamine Biosynthesis PE(14:0/14:0)516
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/14:0) | PE(14:0/14:0)617

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency2.86950.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID86226Compound was tested for its inhibition on growth of human hepatoma cells (Hep-G2); No inhibitory effects was observed2002Bioorganic & medicinal chemistry letters, Nov-18, Volume: 12, Issue:22
Specific accumulation and growth inhibitory effects of hybrid liposomes to hepatoma cells in vitro.
AID214252Compound alone was evaluated for inhibitory effect on growth of glioma (U251) cells; Ineffective2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Highly specific inhibitory effect of three-component hybrid liposomes including sugar surfactants on the growth of glioma cells.
AID214253Compound along with Tween 20 and SucCn was evaluated for inhibitory effect on growth of glioma (U251) cells; Effective2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Highly specific inhibitory effect of three-component hybrid liposomes including sugar surfactants on the growth of glioma cells.
AID362080Selectivity index, ratio of IC50 for HIV 3B infected cells to IC50 for human MOLT4 cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID362079Growth inhibition of HIV1 3B infected human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID362078Growth inhibition of human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,389)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990622 (18.35)18.7374
1990's785 (23.16)18.2507
2000's1015 (29.95)29.6817
2010's815 (24.05)24.3611
2020's152 (4.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.48 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.03%)5.53%
Reviews0 (0.00%)6.00%
Reviews19 (0.55%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.06%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other3,452 (99.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]